Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans

Atherosclerosis

Volumn 205, Issue 2, 2009, Pages 533-537

  Yun, Kyung Eun ^a   Shin, Chan Yim ^a   Yoon, Yeong Sook ^b   Park, Hye Soon ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Alanine aminotransferase; Cardiovascular disease; Mortality; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; MALE; MORTALITY; NONALCOHOLIC FATTY LIVER; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SOUTH KOREA;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FATTY LIVER; FEMALE; HUMANS; KOREA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; RISK; TIME FACTORS;

EID: 67650912354     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.012     Document Type: Article

References (31)

1. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
2. Hu G., Qiao Q., Tuomilehto J., et al. DECODE Study Group: prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164 (2004) 1066-1076
3. International Obesity Task Force. http://www.iotf.org [accessed 20 July 2006].
4. WHO Western Pacific Regional Office. Report on the regional evaluation of noncommunicable diseases prevention and control programme. Manilla; 2005.
5. Bloomgarden Z.T. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 28 (2005) 1518-1523
6. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2002) 1844-1850
7. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
8. Clark J.M., and Diehl A.M. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 289 (2003) 3000-3004
9. Chen C.H., Huang M.H., Yang J.C., et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 22 (2007) 1482-1489
10. Ioannou G.N., Boyko E.J., and Lee S.P. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 101 (2006) 76-82
11. Sattar N., Scherbakova O., Ford I., et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53 (2004) 2855-2860
12. Vozarova B., Stefan N., Lindsay R.S., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 1889-1895
13. Doi Y., Kubo M., Yonemoto K., et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity 15 (2007) 1841-1850
14. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191 (2007) 391-396
15. Ekstedt M., Franzén L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
16. Sorbi D., Boynton J., and Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 94 (1999) 1018-1022
17. Sanyal A.J. American Gastroenterological Association: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 1705-1725
18. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 6 (1972) 499-502
19. Levey A.S., Coresh J., Greene T., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006) 247-254
20. Hanley A.J., Karter A.J., Williams K., et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 112 (2005) 3713-3721
21. International Obesity Task Force. Asia-Pacific perspective: redefining obesity and its treatment. Western Pacific Region, Sydney; 2000.
22. Kaplan M.M. Alanine aminotransferase levels: what's normal?. Ann Intern Med 137 (2002) 49-51
23. Clark J.M., and Diehl A.M. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 124 (2003) 248-250
24. Schindhelm R.K., Diamant M., Dekker J.M., et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22 6 (2006) 437-443
25. Adams L.A., and Talwalkar J.A. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 40 (2006) S34-S38
26. Hanley A.J., Williams K., Festa A., et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54 (2005) 3140-3147
27. Wannamethee S.G., Shaper A.G., Lennon L., and Whincup P.H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28 (2005) 2913-2918
28. Schindhelm R.K., Diamant M., Dekker J.M., et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22 (2006) 437-443
29. Monami M., Bardini G., Lamanna C., et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 57 (2008) 387-392
30. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
31. Pratt D.S., and Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342 (2003) 1266-1271